Gilead Sciences, Inc. $GILD Shares Bought by Steward Partners Investment Advisory LLC

Steward Partners Investment Advisory LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 50,925 shares of the biopharmaceutical company’s stock after acquiring an additional 5,107 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in Gilead Sciences were worth $5,706,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of GILD. Redwood Financial Network Corp grew its position in shares of Gilead Sciences by 4.0% during the fourth quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company’s stock worth $234,000 after buying an additional 98 shares in the last quarter. Argentarii LLC grew its position in shares of Gilead Sciences by 3.0% during the first quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company’s stock worth $380,000 after buying an additional 99 shares in the last quarter. Peak Financial Advisors LLC grew its position in shares of Gilead Sciences by 1.7% during the first quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company’s stock worth $677,000 after buying an additional 100 shares in the last quarter. Perkins Coie Trust Co grew its position in shares of Gilead Sciences by 2.6% during the first quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company’s stock worth $435,000 after buying an additional 100 shares in the last quarter. Finally, Investment Research & Advisory Group Inc. grew its position in shares of Gilead Sciences by 33.3% during the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 100 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Down 0.3%

Gilead Sciences stock opened at $117.99 on Tuesday. The stock has a market cap of $146.40 billion, a price-to-earnings ratio of 23.50, a PEG ratio of 0.73 and a beta of 0.33. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The company’s 50-day moving average price is $111.98 and its two-hundred day moving average price is $108.64. Gilead Sciences, Inc. has a 52 week low of $73.27 and a 52 week high of $121.83.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences’s quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter last year, the company earned $2.01 EPS. On average, analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be given a $0.79 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.7%. Gilead Sciences’s payout ratio is 62.95%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the sale, the insider directly owned 114,168 shares in the company, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $109.74, for a total transaction of $548,700.00. Following the completion of the sale, the director owned 8,920 shares in the company, valued at approximately $978,880.80. This trade represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 110,000 shares of company stock valued at $12,349,790 in the last ninety days. 0.27% of the stock is owned by insiders.

Wall Street Analyst Weigh In

GILD has been the subject of a number of recent analyst reports. UBS Group raised their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research report on Friday, August 8th. Royal Bank Of Canada raised their price objective on Gilead Sciences from $96.00 to $98.00 and gave the stock a “sector perform” rating in a research note on Friday, August 8th. Cantor Fitzgerald initiated coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 price objective on the stock. Needham & Company LLC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective on the stock in a research note on Friday, July 25th. Finally, Morgan Stanley raised their price objective on Gilead Sciences from $130.00 to $135.00 and gave the stock an “overweight” rating in a research note on Friday, April 25th. Seven analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $114.82.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.